Sage Therapeutics (NASDAQ:SAGE - Get Free Report) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.02), Zacks reports. Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%.
Sage Therapeutics Trading Down 0.6 %
SAGE stock traded down $0.04 during midday trading on Friday, reaching $7.14. The stock had a trading volume of 1,943,315 shares, compared to its average volume of 2,832,859. The company's fifty day simple moving average is $6.40 and its 200 day simple moving average is $6.88. The company has a market cap of $436.75 million, a price-to-earnings ratio of -1.28 and a beta of 0.94. Sage Therapeutics has a 52-week low of $4.62 and a 52-week high of $26.25.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on the stock. Royal Bank of Canada raised shares of Sage Therapeutics from an "underperform" rating to a "sector perform" rating and set a $4.00 price objective for the company in a research note on Thursday, November 21st. Oppenheimer lowered their price objective on shares of Sage Therapeutics from $9.00 to $8.00 and set a "market perform" rating for the company in a research note on Wednesday, October 30th. TD Cowen lowered their price objective on shares of Sage Therapeutics from $10.00 to $9.00 and set a "hold" rating for the company in a research note on Thursday, November 21st. Truist Financial lowered their price objective on shares of Sage Therapeutics from $13.00 to $8.00 and set a "hold" rating for the company in a research note on Wednesday, October 30th. Finally, StockNews.com lowered shares of Sage Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, October 31st. Three equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $9.65.
View Our Latest Stock Report on Sage Therapeutics
About Sage Therapeutics
(
Get Free Report)
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Further Reading
Before you consider Sage Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sage Therapeutics wasn't on the list.
While Sage Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
